查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570809

老年失智症症藥物市場：按藥物類別、類型、分佈分類 - 全球預測 2025-2030

Alzheimer's Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

老年失智症症藥物市場2023年估值為61.4億美元，預計2024年將達到66.6億美元，複合年成長率為8.63%，預計到2030年將達到109.6億美元。

老年失智症症的治療範圍包括所有旨在預防、減緩或治療阿茲海默症（一種進行性神經退化性疾病）的產品和化合物。這包括旨在針對阿茲海默症的潛在機制的各種藥物、生技藥品和生活方式干涉措施。世界的老化以及阿茲海默症造成的沉重心理和經濟負擔強調了開發有效治療方法的必要性。阿茲海默症症藥物主要用於醫院、診所和專門護理機構等醫療環境，重點是改善患者的生活品質和減輕看護者的負擔。最終用途範圍廣泛，包括製藥公司、研究實體、醫療保健提供者和患者本身。

主要市場統計
基準年[2023] 61.4億美元
預測年份 [2024] 66.6億美元
預測年份 [2030] 109.6億美元
複合年成長率（%） 8.63%

該市場的關鍵成長要素包括阿茲海默症的日益普及、生物技術的進步、合作研究和開發的激增以及政府資助神經科學研究的舉措。機會在於開發疾病修正治療、透過生物標記進行的個人化醫療以及用於早期診斷和監測的創新數位工具。鼓勵相關人員利用官民合作關係關係並在藥物發現中利用人工智慧來增強其競爭地位。然而，新興市場面臨藥物開發成本高、核准流程長、後期臨床試驗結果令人失望以及對疾病病理學了解有限等限制。

挑戰包括監管障礙、報銷問題以及阿茲海默症，這些都使藥物開發變得複雜。創新和研究應著重於新的治療方法，例如基因治療藥物，探索腸腦軸的影響，並利用多組學體學進行生物標記識別。市場仍然競爭激烈且研究密集型，需要不斷創新才能滿足監管標準和消費者期望。公司應優先考慮適應性策略，例如動態臨床試驗模型和與高科技公司的合作夥伴關係，以促進強勁的市場成長。對於希望在老年失智症症藥物領域取得成功的公司來說，積極主動、敏捷地應對這些多樣化的挑戰至關重要。

市場動態：揭示快速發展的老年失智症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變老年失智症症藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，以及消費行為及其對製造成本的影響及其對採購趨勢的影響。

波特五力：駕馭老年失智症症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解老年失智症症藥物市場的外部影響

外部宏觀環境因素在塑造老年失智症症藥物市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解老年失智症治療藥物市場的競爭狀況

對老年失智症症藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 在老年失智症症治療市場的定位矩陣供應商績效評估

FPNV定位矩陣是評估老年失智症治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，規劃老年失智症症藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，老年失智症症藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 阿茲海默症在人群中的發生率不斷上升
      • 擴大管道藥物開發和供應
      • 改善醫療設施和技術以早期發現阿茲海默症
    • 抑制因素
      • 阿茲海默症的資本密集型治療
    • 機會
      • 結合雲端基礎的認知系統和人工智慧的密集研發
      • 新生物標記和再生醫學的開發
    • 任務
      • 嚴格的醫藥品認證過程
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章老年失智症藥物市場：依藥物類別

  • 介紹
  • 膽鹼酯酶抑制劑
  • NMDA [N-甲基-D-天門冬胺酸]受體拮抗劑

第7章老年失智症藥物市場：按類型

  • 介紹
  • 藥物治療
    • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • Galantamine
    • Rivastigmine
  • NMDA受體拮抗劑

第8章老年失智症症藥物市場：依分佈

  • 介紹
  • 網路藥房
  • 零售藥房

第9章 美洲老年失智症症藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太老年失智症症藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲老年失智症藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 老年失智症治療的下一階段使用阿圖他汀 ACD680
    • Arzecure 選擇 CD 進行阿茲海默症藥物阿圖他汀 ACD680 的下一階段開發
  • 戰略分析和建議
Product Code: MRR-A77F2EE7AADB

The Alzheimer's Therapeutics Market was valued at USD 6.14 billion in 2023, expected to reach USD 6.66 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 10.96 billion by 2030.

The scope of Alzheimer's therapeutics encompasses all products and compounds aimed at preventing, slowing, or treating Alzheimer's disease, a progressive neurodegenerative disorder. This includes a range of pharmaceuticals, biologics, and lifestyle interventions designed to target the underlying mechanisms of Alzheimer's. The necessity of developing effective treatments is underscored by the aging global population and the high emotional and economic burden of Alzheimer's. Its application is primarily in healthcare settings-hospitals, clinics, and specialized care facilities-focusing on improving patient quality of life and reducing caregiver strain. The end-use scope is vast, encompassing pharmaceutical companies, research institutions, healthcare providers, and patients themselves.

KEY MARKET STATISTICS
Base Year [2023] USD 6.14 billion
Estimated Year [2024] USD 6.66 billion
Forecast Year [2030] USD 10.96 billion
CAGR (%) 8.63%

Key growth factors in this market include increasing prevalence rates of Alzheimer's, advancements in biotechnology, a surge in collaborative R&D efforts, and government initiatives funding neuroscience research. Opportunities lie in the development of disease-modifying therapies, personalized medicine through biomarkers, and breakthrough digital tools for early diagnosis and monitoring. It is recommended that stakeholders tap into public-private partnerships and leverage artificial intelligence for drug discovery to enhance their competitive positioning. However, the market faces limitations such as high drug development costs, lengthy approval processes, disappointing late-stage clinical trial results, and limited understanding of disease pathology.

Challenging factors include regulatory hurdles, reimbursement issues, and the complex multi-faceted etiology of Alzheimer's that complicates treatment development. Innovation and research should focus on novel therapeutic modalities like gene therapy, exploring the gut-brain axis influence, and leveraging multi-omics approaches for biomarker identification. The market's nature remains highly competitive and research-intensive, with a need for continual innovation to meet regulatory standards and consumer expectations. Firms should prioritize adaptive strategies, such as dynamic clinical trial models and partnerships with tech companies, to foster robust market growth. Addressing these diverse challenges through proactivity and agility will be crucial for businesses aiming to succeed in the Alzheimer's therapeutics landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alzheimer's Therapeutics Market

The Alzheimer's Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of Alzheimer's among population
    • Growing development and availability of pipeline drugs
    • Improved healthcare facilities and technologies for early detection of Alzheimer's
  • Market Restraints
    • Capital intensive treatment for Alzheimer's
  • Market Opportunities
    • Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
    • Development of novel biomarkers and emerging regenerative therapies
  • Market Challenges
    • Stringent drug approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Alzheimer's Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alzheimer's Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alzheimer's Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alzheimer's Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alzheimer's Therapeutics Market

A detailed market share analysis in the Alzheimer's Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alzheimer's Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alzheimer's Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alzheimer's Therapeutics Market

A strategic analysis of the Alzheimer's Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alzheimer's Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., AlzeCure Pharma AB, Alzheon, Inc., AstraZeneca PLC, Biogen Inc., Cassava Sciences, Inc., Cognition Therapeutics, Inc., Corium, Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Grifols S.A., H. Lundbeck A/S, Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, NeuroVision Imaging, Inc., Novartis AG, Oryzon Genomics, S.A., Pfizer, Inc., Siemens Healthcare GmbH, Synaptogenix, Inc., TauRx Pharmaceuticals Ltd., and VTV Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Alzheimer's Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Cholinesterase Inhibitors and NMDA [N-methyl-D-aspartate] Receptor Antagonist.
  • Based on Type, market is studied across Medication and NMDA Receptor Antagonist. The Medication is further studied across Cholinesterase inhibitors, Donepezil, Galantamine, and Rivastigmine.
  • Based on Distribution, market is studied across Online Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of Alzheimer's among population
      • 5.1.1.2. Growing development and availability of pipeline drugs
      • 5.1.1.3. Improved healthcare facilities and technologies for early detection of Alzheimer's
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment for Alzheimer's
    • 5.1.3. Opportunities
      • 5.1.3.1. Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
      • 5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent drug approval processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alzheimer's Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Cholinesterase Inhibitors
  • 6.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist

7. Alzheimer's Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Medication
    • 7.2.1. Cholinesterase inhibitors
    • 7.2.2. Donepezil
    • 7.2.3. Galantamine
    • 7.2.4. Rivastigmine
  • 7.3. NMDA Receptor Antagonist

8. Alzheimer's Therapeutics Market, by Distribution

  • 8.1. Introduction
  • 8.2. Online Pharmacies
  • 8.3. Retail Pharmacies

9. Americas Alzheimer's Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alzheimer's Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alzheimer's Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. The Next Phase of Alzheimer's Therapeutics with Alzstatin ACD680
    • 12.3.2. Alzecure Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AC Immune SA
  • 3. Acadia Pharmaceuticals Inc.
  • 4. Alnylam Pharmaceuticals, Inc.
  • 5. AlzeCure Pharma AB
  • 6. Alzheon, Inc.
  • 7. AstraZeneca PLC
  • 8. Biogen Inc.
  • 9. Cassava Sciences, Inc.
  • 10. Cognition Therapeutics, Inc.
  • 11. Corium, Inc.
  • 12. Eisai Co., Ltd.
  • 13. Eli Lilly and Company
  • 14. F. Hoffmann-La Roche Ltd.
  • 15. Grifols S.A.
  • 16. H. Lundbeck A/S
  • 17. Luye Pharma Group Ltd.
  • 18. Merz Pharma GmbH & Co. KGaA
  • 19. NeuroVision Imaging, Inc.
  • 20. Novartis AG
  • 21. Oryzon Genomics, S.A.
  • 22. Pfizer, Inc.
  • 23. Siemens Healthcare GmbH
  • 24. Synaptogenix, Inc.
  • 25. TauRx Pharmaceuticals Ltd.
  • 26. VTV Therapeutics

LIST OF FIGURES

  • FIGURE 1. ALZHEIMER'S THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALZHEIMER'S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALZHEIMER'S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALZHEIMER'S THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALZHEIMER'S THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. ALZHEIMER'S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. ALZHEIMER'S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023